These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12556085)

  • 1. No need to measure serum aluminum in patients starting chronic ambulatory peritoneal dialysis.
    Musso CG; Bailey S; Shu M; Liakopoulos VC; Savaj S; Ghareeb S; Sahu K; Oreopoulos DG
    Perit Dial Int; 2002; 22(6):738. PubMed ID: 12556085
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum aluminum and continuous ambulatory peritoneal dialysis.
    Wolf A; Graf H; Pinggera WF; Stummvoll HK; Meisinger V
    Ann Intern Med; 1980 Jan; 92(1):130-1. PubMed ID: 7350863
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum concentration and peritoneal transfer of aluminum during treatment by continuous ambulatory peritoneal dialysis.
    Rottembourg J; Gallego JL; Jaudon MC; Clavel JP; Legrain M
    Kidney Int; 1984 Jun; 25(6):919-24. PubMed ID: 6471674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P; Allain P; Ang KS; Cam G; Mauras Y
    Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
    Romero RA; Salgado O; Elejalde LE; Rodríguez-Iturbe B; Tahán JE
    Transplant Proc; 1996 Dec; 28(6):3385-7. PubMed ID: 8962321
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of magnesium hydroxide and low magnesium dialysate does not permit reduction of aluminum hydroxide during continuous ambulatory peritoneal dialysis.
    Jennings AE; Bodvarsson M; Galicka-Piskorska G; Diefendorf AS; Simon GM; Levey AS
    Am J Kidney Dis; 1986 Sep; 8(3):192-5. PubMed ID: 3752074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
    Andreoli SP; Dunn D; DeMyer W; Sherrard DJ; Bergstein JM
    J Pediatr; 1985 Nov; 107(5):760-3. PubMed ID: 3932629
    [No Abstract]   [Full Text] [Related]  

  • 8. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Joffe P; Olsen F; Heaf JG; Gammelgaard B; Pödenphant J
    Clin Nephrol; 1989 Sep; 32(3):133-8. PubMed ID: 2791364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with aluminum-associated bone disease in end-stage renal disease patients.
    Joglar FM; Rivera CG; Burgos R; Huffer WE
    Transplant Proc; 1991 Apr; 23(2):1823-4. PubMed ID: 2053166
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis and methods for early recognition of aluminium intoxication.
    Fuchs C; Armstrong VW; Quellhorst E; Scheler F
    Contrib Nephrol; 1984; 38():81-94. PubMed ID: 6713903
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of plasma aluminum in the detection and prevention of aluminum toxicity.
    Winney RJ; Cowie JF; Robson JS
    Kidney Int Suppl; 1986 Feb; 18():S91-5. PubMed ID: 3458005
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum myoglobin in patients on intermittent and continuous ambulatory peritoneal dialysis.
    Feinfeld DA; Verger C; Briscoe AM; Hotchkiss JL; Nurse HM; Merlin F; Nair S; Hart PM
    Clin Nephrol; 1987 Sep; 28(3):144-6. PubMed ID: 3665208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution of the serum aluminum values in the Piedmont dialysis population. Dialysis Centers of the Piedmont].
    Fidelio T; Licata C; Serra A; Scalzo B; Deabate MC; Sancipriano GP; Iacono G; Calitri V
    Minerva Urol Nefrol; 1994 Mar; 46(1):73-6. PubMed ID: 8036558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does low-calcium dialysate accelerate secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients?
    Rotellar C; Kinsel V; Goggins M; Tarman G; Stull M; Mazzoni MJ; Mosher WF; Rakowski TA; Winchester JF
    Perit Dial Int; 1993; 13 Suppl 2():S471-2. PubMed ID: 8399643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intermittent peritoneal dialysis and continuous ambulatory peritoneal dialysis].
    Radovanović Lj; Popović J; Radlović O
    Srp Arh Celok Lek; 1988; 116(11-12):967-76. PubMed ID: 3247614
    [No Abstract]   [Full Text] [Related]  

  • 17. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low serum CA125 concentration in chronic renal failure treated with continuous ambulatory peritoneal dialysis.
    Kawabe T; Ishii M; Sugimoto T; Tagawa H
    Clin Chim Acta; 1987 Sep; 168(1):113-4. PubMed ID: 3478159
    [No Abstract]   [Full Text] [Related]  

  • 19. [Continuous ambulatory peritoneal dialysis (CAPD)].
    Mydlík M; Derzsiová K; Válek A; Takác M
    Vnitr Lek; 1982 Jun; 28(6):602-8. PubMed ID: 7112984
    [No Abstract]   [Full Text] [Related]  

  • 20. Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoneal dialysis compared with hemodialysis.
    Shusterman NH; Wasserstein AG; Morrison G; Audet P; Fallon MD; Kaplan F
    Am J Med; 1987 Jun; 82(6):1148-56. PubMed ID: 3605132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.